NCT00513383 - Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2012

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Panitumumab

Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A

DRUG

Carboplatin

Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

DRUG

Paclitaxel

Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

RADIATION

Intensity Modulated Radiation Therapy

Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks

DRUG

5-Fluorouracil

Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles

DRUG

Docetaxel

Intravenously on day 1 of a 21-day cycle for 3 cycles

DRUG

Cisplatin

Intravenously on day 1 of a 21-day cycle for 3 cycles

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston